Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Pharmacokinetics of a Novel NMDA Receptor Antagonist Against Brain Related Diseases in Healthy Adult Volunteers: First-in-human, Phase I, Single Dose-escalating, Open Label Study

NCT05921929 is registered in ClinicalTrials.gov with ReST Therapeutics as lead sponsor.

NCT NCT05921929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05921929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Pharmacokinetics of a Novel NMDA Receptor Antagonist Against Brain Related Diseases in Healthy Adult Volunteers: First-in-human, Phase I, Single Dose-escalating, Open Label Study
Lead sponsor
ReST Therapeutics
Phase
Phase 1
Overall status
Withdrawn
Start date
May 2, 2024
Completion date
May 2, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, brain diseases, major depressive disorder, neuro-degenerative disease, ptsd, treatment resistant depression